BRCA2 Mutation

BRCA Founder OutReach (BFOR) Study

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Evaluating Cascade Communication Methods

Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy

Radical Fimbriectomy for Young BRCA Mutation Carriers

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Functional Analysis of BRCAness

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

BRCA Mutation Carriers' Platform a Multicenter Study

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

Genetic Education in BRCA Families